Previous 10 | Next 10 |
2024-04-12 12:59:27 ET More on Cerus Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS ...
2024-04-12 09:30:05 ET Craig-Hallum analyst issues BUY recommendation for CERS on April 12, 2024 07:19AM ET. CERS was trading at $1.695 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from th...
2024-03-19 08:47:37 ET More on Cerus Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS Seeking Alpha’s Quant Rating on Cerus Historical earnings data for Cerus Fin...
Trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury for INTERCEPT Red Blood Cells compared to conventional red blood cells Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 cl...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
Cerus Corporation (NASDAQ: CERS) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 24.87% on the day to $2.48. Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializ...
2024-03-05 18:43:13 ET Cerus Corporation (CERS) Q4 2023 Earnings Conference Call March 05, 2024, 04:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Kevin Green - Vice Preside...
2024-03-05 16:01:24 ET More on Cerus Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS Seeking Alpha’s Quant Rating on Cerus Historical earnings data for Cerus Financial information for Cerus Read the full article on Se...
Sequential Revenue Growth in the Fourth Quarter Driven by Sales in North America Narrowed GAAP Net Loss Attributable to Cerus Corporation to $1.3 Million for the Fourth Quarter and Achieved Goal of Adjusted EBITDA Breakeven for the Fourth Quarter Reiterating Full-Year 2024 Product...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...
Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply...